TIDMHIK
RNS Number : 9273E
Hikma Pharmaceuticals Plc
16 May 2013
Hikma Pharmaceuticals PLC
Results of 2013 Annual General Meeting
LONDON, 16 May 2013 - Hikma Pharmaceuticals PLC ("the Company")
advises that at its Annual General Meeting of shareholders, held at
The Westbury, Bond Street, Mayfair, London W1S 2YF that commenced
at 11:00 am today, 16 May 2013, all resolutions were passed on a
poll. Resolutions 1 to 16, 20 and 21 were passed as ordinary
resolutions and Resolutions 17 to 19 were passed as special
resolutions.
Copies of the resolutions dealing with special business passed
at the Annual General Meeting have been submitted to the UK Listing
Authority for publication through the Listing Authority's Document
Viewing Facility.
The total number of votes cast on the poll for each resolution
is set out below. The number of Ordinary Shares in issue on 16 May
2013 was 197,886,828
Resolution Votes For % Votes % Votes Withheld
Against
--- ------------------------------ ------------ -------- ----------- ------- ---------------
To receive the 2012
1 report and accounts 152,502,069 99.68% 491,618 0.32% 103,667
--- ------------------------------ ------------ -------- ----------- ------- ---------------
To declare a final dividend
2 of 10 cents per share 153,092,859 100.00% 0 0.00% 4,495
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Reappointment of Deloitte
3 LLP as auditors 151,574,655 99.09% 1,389,041 0.91% 133,658
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Authorise the directors
to set the remuneration
4 of the auditors 152,095,460 99.43% 868,236 0.57% 133,658
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Reappointment of Samih
5 Darwazah 150,329,864 98.38% 2,472,348 1.62% 295,142
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Reappointment of Said
6 Darwazah 152,430,942 99.76% 371,270 0.24% 295,142
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Reappointment of Mazen
7 Darwazah 148,055,378 96.89% 4,746,834 3.11% 295,142
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Reappointment of Breffni
8 Byrne 152,039,142 99.68% 493,070 0.32% 295,142
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Reappointment of Sir
9 David Rowe-Ham 152,287,697 99.66% 514,515 0.34% 295,142
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Reappointment of Michael
10 Ashton 152,327,197 99.69% 475,015 0.31% 295,142
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Reappointment of Ali
11 Al-Husry 151,811,434 99.35% 990,778 0.65% 295,142
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Reappointment of Ronald
12 Goode 152,349,142 99.70% 453,070 0.30% 295,142
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Reappointment of Robert
13 Pickering 147,267,668 99.69% 453,070 0.31% 5,376,616
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Approve the 2013 remuneration
14 policy 146,130,652 99.31% 1,017,508 0.69% 5,949,194
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Approve the 2012 remuneration
15 implementation 146,130,652 99.31% 1,017,508 0.69% 5,949,194
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Authorise the directors
16 to allot shares 121,831,792 82.92% 25,096,921 17.08% 6,168,641
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Disapply pre-emption
17 rights 147,702,491 99.80% 295,142 0.20% 5,099,721
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Authorise the company
18 to buy back shares 147,315,385 99.53% 696,000 0.47% 5,085,969
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Authorise the company
to call meetings on
19 14 days notice 137,330,961 92.78% 10,684,919 7.22% 5,081,474
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Rule 9 waiver for buy
20 backs 115,354,213 78.71% 31,210,707 21.29% 6,532,434
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Rule 9 waiver for LTIP
21 & MIP awards 115,367,965 78.14% 32,279,627 21.86% 5,449,762
--- ------------------------------ ------------ -------- ----------- ------- ---------------
Waiver of Rule 9 of the City Code on Takeovers and Mergers
In relation to Resolutions 20 and 21, at today's date, the total
number of ordinary shares held by the Concert Party, is 63,810,460
representing a combined shareholding of 32.25 per cent of the
issued share capital of the Company.
Assuming the Share Awards are made in respect of the full number
of shares referred to in the circular to shareholders dated 10
April 2013, that all such grants vest in full, and that all
existing awards LTIP Awards vest in full, and that all Options
currently held by members of the Concert Party were to be fully
exercised and the resulting Ordinary Shares retained by the Concert
Party members, the Concert Party would hold, in aggregate,
interests over 64,522,267 Ordinary Shares, representing 32.50 per
cent of the issued share capital of the Company (as enlarged by the
existing LTIP and MIP Awards and Option Exercises by members of the
Concert Party and the issue of Ordinary Shares to members of the
Concert Party pursuant to the Share Awards, but assuming no other
issue of shares) versus 32.61 per cent of the issued share capital
of the Company on a similar basis, prior to the grant of such Share
Awards.
Were the Company to exercise the buy-back authority to the
exclusion of the Concert Party such that the Concert Party
maintained its current shareholding, that would result in the
Concert Party's percentage interest in the Company's issued share
capital increasing to 36.64 per cent. (assuming that all Existing
LTIP Awards vest in full and all Options held by members of the
Concert Party are exercised and the resulting Ordinary Shares are
retained, but not including the Share Awards granted under
Resolution 21).
If the maximum repurchase of Ordinary Shares authorised was
carried out by the Company and also the maximum number of Share
Awards vested, together with the Existing LTIP Awards and Option
Exercises these changes would increase the aggregate shareholding
of the Concert Party in the Company to 36.12 per cent. (assuming
that that the Concert Party did not sell any Ordinary Shares in the
repurchase of Ordinary Shares and assuming no other issue of
Ordinary Shares).
Declaration of final dividend
The final dividend of 10.0 cents per share will be paid on 23
May 2013 to shareholders on the register on 19 April 2013.
Shareholders who are not resident in Jordan have been given the
option of receiving their dividend in Pounds Sterling. The exchange
rate in respect of this dividend will be $1.5373 to GBP1. The
exchange rate for Jordanian Dinar is fixed to the US Dollar at 1JD
to $0.708.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2670
Susan Ringdal
VP for Investor Relations and Strategy +44 20 7399 2670
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2012, Hikma achieved
revenues of $1,108.7 million and profit attributable to
shareholders of $100.3 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGSFAFLMFDSEEI
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
